Portal de Periódicos da CAPES

Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study

2020; Elsevier BV; Volume: 141; Linguagem: Inglês

10.1016/j.ejca.2020.09.027

1879-0852

Karlijn de Joode, Daphne W. Dumoulin, Jolien Tol, Hans M. Westgeest, Laurens V. Beerepoot, Franchette W.P.J. van den Berkmortel, Pim Mutsaers, Nico G. J. van Diemen, Otto Visser, Esther Oomen‐de Hoop, Haiko J. Bloemendal, Hanneke W.M. van Laarhoven, Lizza E.L. Hendriks, John B.A.G. Haanen, Elisabeth G.E. de Vries, Anne‐Marie C. Dingemans, Astrid A.M. van der Veldt, C.J. van Loenhout, Cor H. van der Leest, Annemarie Becker‐Commissaris, Jessica S.W. Borgers, F. Terhegggen, Ben E.E.M. van den Borne, L.J.C. van Warmerdam, L. van Leeuwen, Femke S. van der Meer, M. Tiemessen, D.M. van Diepen, Yarne Klaver, A.P. Hamberg, Eduard J. Libourel, Luc J. A. Strobbe, Marissa Cloos, Erica J. Geraedts, Jan C. Drooger, Raban Heller, Jan Willem B. de Groot, Jos A. Stigt, Veerle J. Nuij, Cordula Pitz, Marije Slingerland, Frank J. Borm, Brigitte C.M. Haberkorn, Susan C. van ‘t Westeinde, Maureen J.B. Aarts, J.W.G. van Putten, Mina Youssef, Geert A. Cirkel, Gerarda J.M. Herder, C. R. van Rooijen, Emanuel Citgez, Nicole P. Barlo, Béatrice Scholtes, Rutger H.T. Koornstra, Niels Claessens, Laura M. Faber, C.H. Rikers, R.A.W. van de Wetering, Gerald Veurink, B.W. Bouter, Ilse Houtenbos, Mathieu Bard, Karin H. Herbschleb, Elisabeth A. Kastelijn, Pepijn Brocken, Gea Douma, Mathilde Jalving, T. Jeroen N. Hiltermann, Olga C.J. Schuurbiers-Siebers, Karijn P.M. Suijkerbuijk, Anne S. R. van Lindert, Agnès J. van de Wouw, Vivian E. M. van Kampen‐van den Boogaart, Sandra D. Bakker, E. Looysen, A.L. Peerdeman, Wouter K. de Jong, Ester Siemerink, Ada Staal, Bas Franken, Wouter H. van Geffen, Gerben Bootsma,

Cancer survivorship and care

Aim of the studyPatients with cancer might have an increased risk for severe outcome of coronavirus disease 2019 (COVID-19). To identify risk factors associated with a worse outcome of COVID-19, a nationwide registry was developed for patients with cancer and COVID-19.MethodsThis observational cohort study has been designed as a quality of care registry and is executed by the Dutch Oncology COVID-19 Consortium (DOCC), a nationwide collaboration of oncology physicians in the Netherlands. A questionnaire has been developed to collect pseudonymised patient data on patients' characteristics, cancer diagnosis and treatment. All patients with COVID-19 and a cancer diagnosis or treatment in the past 5 years are eligible.ResultsBetween March 27th and May 4th, 442 patients were registered. For this first analysis, 351 patients were included of whom 114 patients died. In multivariable analyses, age ≥65 years (p < 0.001), male gender (p = 0.035), prior or other malignancy (p = 0.045) and active diagnosis of haematological malignancy (p = 0.046) or lung cancer (p = 0.003) were independent risk factors for a fatal outcome of COVID-19. In a subgroup analysis of patients with active malignancy, the risk for a fatal outcome was mainly determined by tumour type (haematological malignancy or lung cancer) and age (≥65 years).ConclusionThe findings in this registry indicate that patients with a haematological malignancy or lung cancer have an increased risk of a worse outcome of COVID-19. During the ongoing COVID-19 pandemic, these vulnerable patients should avoid exposure to severe acute respiratory syndrome coronavirus 2, whereas treatment adjustments and prioritising vaccination, when available, should also be considered.